Drugs / FDA018-ADC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05174637 | Oct 2021 → Dec 2029 expected | — | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06519370 | Aug 2024 → Aug 2026 overdue | triple-negative breast carcinoma | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FDA018-ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05174637 ↗ |
| Route | Intravenous | “an intravenous infusion of FDA018-ADC” NCT05174637 ↗ |